The objective of this study is to determine if citocoline is effective for balance
abnormalities and to stabilize cognitive decline in patients with fragile X-associated tremor
ataxia syndrome. The study will test 1000mg twice daily of citocoline for 12 months in an
open label pilot study, with study visits at baseline, 3, 6, and 12 months.